Abstract
Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5463-5474 |
| Number of pages | 12 |
| Journal | Journal of Biological Chemistry |
| Volume | 288 |
| Issue number | 8 |
| DOIs | |
| State | Published - Feb 22 2013 |
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Cell Biology
Fingerprint Dive into the research topics of 'Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth'. Together they form a unique fingerprint.
Cite this
Wu, F., Peacock, S. O., Rao, S., Lemmon, S. K., & Burnstein, K. L. (2013). Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth. Journal of Biological Chemistry, 288(8), 5463-5474. https://doi.org/10.1074/jbc.M112.390963